Yang, Q, Rasmussen, SA, Friedman, J.
Mortality associated with Down's syndrome in the USA from 1983 to 1997: a population-based study. Lancet
2002; 359: 1019–25.
Englund, A, Jonsson, B, Zander, CS, Gustafsson, J, Annerén, G.
Changes in mortality and causes of death in the Swedish Down syndrome population. Am J Med Genet A
2013; 161: 642–9.
Wiseman, FK, Al-Janabi, T, Hardy, J, Karmiloff-Smith, A, Nizetic, D, Tybulewicz, VL, et al.
A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome. Nat Rev Neurosci
2015; 16: 564–74.
Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev
2006; 1: CD005593.
McShane, R, Areosa Sastre, A, Minakaran, N.
Memantine for dementia. Cochrane Database Syst Rev
2006; 2: CD003154.
Mohan, M, Bennett, C, Carpenter, PK.
Galantamine for dementia in people with Down syndrome. Cochrane Database Syst Rev
2009; 1: CD007656.
Mohan, M, Bennett, C, Carpenter, PK.
Rivastigmine for dementia in people with Down syndrome. Cochrane Database Syst Rev
2009; 1: CD007658.
Mohan, M, Carpenter, PK, Bennett, C.
Donepezil for dementia in people with Down syndrome. Cochrane Database Syst Rev
2009; 1: CD007178.
Hanney, M, Prasher, V, Williams, N, Jones, EL, Aarsland, D, Corbett, A, et al.
Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial. Lancet
2012; 379: 528–36.
Sheehan, R, Sinai, A, Bass, N, Blatchford, P, Bohnen, I, Bonell, S, et al.
Dementia diagnostic criteria in Down syndrome. Int J Geriatr Psychiatry
2015; 30: 857–63.
Royal College of Psychiatrists and the British Psychological Society. Dementia and People with Intellectual Disabilities. The British Psychological Society, 2015.
Eurlings, HAL, Evenhuis, HM, Kengen, MMF.
Dementia Questionnaire for People with Learning Disabilities (DLD). UK adaptation. Harcourt Assessment, 2006.
Evaluation of a screening instrument for dementia in ageing mentally retarded persons. J Intell Disabil Res
1992; 36: 337–47.
Dementia questionnaire for persons with mental retardation (DMR): modified criteria for adults with Down's syndrome. J Appl Res Intellect
1997; 10: 54–60.
McCarron, M, McCallion, P, Reilly, E, Mulryan, N.
A prospective 14-year longitudinal follow-up of dementia in persons with Down syndrome. J Intell Disabil Res
2014; 58: 61–70.
Practical Statistics for Medical Research. Chapman and Hall, 1991.
Nonparametric methods of estimating survival functions. In Statistical Methods for Survival Data Analysis (3rd edn) (eds Lee, ET and Wang, J): 64–105. John Wiley & Sons, 2003.
Regression Modeling Strategies: with Applications to Linear Models, Logistic and Ordinal Regression, and Survival Analysis. Springer, 2015.
Mickey, R, Greenland, S.
A study of the impact of confounder-selection criteria on effect estimation. Am J Epidemiol
1989; 129: 125–37.
Ambler, G, Seaman, S, Omar, R.
An evaluation of penalised survival methods for developing prognostic models with rare events. Stat Med
2012; 31: 1150–61.
Wu, C-Y, Hu, H-Y, Chow, L-H, Chou, YJ, Huang, N, Wang, PN, et al.
The effects of anti-dementia and nootropic treatments on the mortality of patients with dementia: a population-based cohort study in Taiwan. PloS One
2015; 10: e0130993.
Zhu, CW, Livote, EE, Scarmeas, N, Albert, M, Brandt, J, Blacker, D, et al.
Long-term associations between cholinesterase inhibitors and memantine use and health outcomes among patients with Alzheimer's disease. Alzheimers Dement
2013; 9: 733–40.
Suh, G-H, Ryu, S-H, Lee, D-W, Han, C, Ju, YS, Kee, BS, et al.
Cholinesterase inhibitors for Alzheimer disease: do they provide more than symptomatic benefits?
Am Geriatr Psychiatry
2011; 19: 266–73.
Rountree, SD, Chan, W, Pavlik, VN, Darby, EJ, Doody, RS.
Factors that influence survival in a probable Alzheimer disease cohort. Alzheimers Res Ther
2012; 4: 16.
Nordström, P, Religa, D, Wimo, A, Winblad, B, Eriksdotter, M.
The use of cholinesterase inhibitors and the risk of myocardial infarction and death: a nationwide cohort study in subjects with Alzheimer's disease. Eur Heart J
2013; 34: 2585–91.
Vis, J, Duffels, M, Winter, M, Weijerman, ME, Cobben, JM, Huisman, SA, et al.
Down syndrome: a cardiovascular perspective. J Intell Disabil Res
2009; 53: 419–25.
Lott, IT, Osann, K, Doran, E, Nelson, L.
Down syndrome and Alzheimer disease: response to donepezil. Arch Neurol
2002; 59: 1133–6.
Prasher, V, Fung, N, Adams, C.
Rivastigmine in the treatment of dementia in Alzheimer's disease in adults with Down syndrome. Int J Geriatr Psychiatry
2005; 20: 496–7.
Prasher, V, Huxley, A, Haque, M.
A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Down syndrome and Alzheimer's disease—pilot study. Int J Geriatr Psychiatry
2002; 17: 270–8.
Prasher, V, Sachdeva, N, Adams, C, Haque, M.
Rivastigmine transdermal patches in the treatment of dementia in Alzheimer's disease in adults with Down syndrome-pilot study. Int J Geriatr Psychiatry
2013; 28: 219–20.
Atri, A, Hendrix, SB, Pejović, V, Hofbauer, RK, Edwards, J, Molinuevo, JL, et al.
Cumulative, additive benefits of memantine-donepezil combination over component monotherapies in moderate to severe Alzheimer's dementia: a pooled area under the curve analysis. Alzheimers Res Ther
2015; 7: 28.
Kishnani, PS, Sullivan, JA, Walter, BK, Spiridigliozzi, GA, Doraiswamy, PM, Krishnan, KRR.
Cholinergic therapy for Down's syndrome. Lancet
1999; 353: 1064–5.
Perera, G, Khondoker, M, Broadbent, M, Breen, G, Stewart, R.
Factors associated with response to acetylcholinesterase inhibition in dementia: a cohort study from a secondary mental health care case register in London. PloS One
2014; 9: e109484.
Dubois, B, Chupin, M, Hampel, H, Lista, S, Cavedo, E, Croisile, B, et al.
Donepezil decreases annual rate of hippocampal atrophy in suspected prodromal Alzheimer's disease. Alzheimers Dement
2015; 11: 1041–9.
National Institute for Health and Care Excellence. Dementia: Supporting People with Dementia and their Carers in Health and Social Care. CG42. National Institute for Health and Care Excellence, 2006.
Kishnani, PS, Spiridigliozzi, GA, Heller, JH, Sullivan, JA, Doraiswamy, PM, Krishnan, KRR.
Donepezil for Down's syndrome. Am J Psychiatry
2001; 158: 143.
Janicki, MP, Dalton, AJ.
Prevalence of dementia and impact on intellectual disability services. Ment Retard
2000; 38: 276–88.
Cleves, , et al.
An Introduction to Survival Analysis Using Stata, Revised Third Edition. College Station, Texas: Stata Press, 2016.